Aardvark Therapeutics Stock Surges as FDA Lifts Clinical Hold After Cardiac Safety Concerns
Aardvark Therapeutics shares jumped 25.06% after hours as the FDA lifted its clinical hold on ARD-101 development.
Share
Why It Matters
The FDA said Aardvark can test its medicine again after safety checks. When a company gets permission like this, it shows progress, but testing still takes time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.